Skip to content

A Multicenter, Prospective, Single-Arm, Investigator-Initiated Study Evaluating the Efficacy and Safety of Expandable Cages in Transforaminal Lumbar Interbody Fusion: Focus on Fusion Rates and Adjacent Segment Disease Incidence

A Multicenter, Prospective, Single-Arm, Investigator-Initiated Study Evaluating the Efficacy and Safety of Expandable Cages in Transforaminal Lumbar Interbody Fusion: Focus on Fusion Rates and Adjacent Segment Disease Incidence

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0010912
Enrollment
20
Registered
2025-08-19
Start date
2025-10-01
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Intervention Name: Transforaminal Lumbar Interbody Fusion (TLIF) using the Excender expandable cage Type of Intervention: Surgical implantation of a spinal interbody fusion device D

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adults aged =19 years Patients requiring 1–2 level TLIF between L1 and S1 for degenerative lumbar spine disease Failed =3 months of conservative treatment, with supporting radiologic findings and persistent symptoms (e.g., low back pain, leg pain) Willing to provide written informed consent and comply with scheduled visits and study procedures

Exclusion criteria

Exclusion criteria: Inmates or prisoners; pregnant or breastfeeding women Poor cartilage quality, active infections, hypersensitivity or allergy to device materials (Titanium, PEEK, Tantalum) Hemorrhagic disorders (e.g., hemophilia), immunosuppression, or preexisting infections that could delay healing Non-degenerative spinal conditions (e.g., trauma, tumor, spinal infections) Severe cardiac/liver disease, osteomalacia, Paget’s disease Uncooperative behavior, cognitive impairment, or inability to comply with follow-up Planned emigration within 2 years or otherwise deemed inappropriate by investigator

Design outcomes

Primary

MeasureTime frame
Fusion rate at 12 months postoperatively (defined by radiographic/CT fusion mass and <3° Cobb angle difference on flexion-extension view)

Secondary

MeasureTime frame
Improvement in Visual Analog Scale (VAS) scores for back and leg pain at 3, 6, and 12 months postoperatively compared to baseline;Improvement in Oswestry Disability Index (ODI) scores at 3, 6, and 12 months postoperatively compared to baseline;Incidence of adjacent segment degeneration (ASD) at 12 months postoperatively

Countries

Korea, Republic of

Contacts

Public ContactSun-Oak Jee

Asan Medical Center

kenzo718@nate.com+82-2-1688-7575

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026